Shire and Hydromed Sciences Realign Agreement for the Development and Marketing of Histrelin for Prostate Cancer
Under the terms of the realigned agreement, HydroMed will be responsible for concluding the Phase III development, filing for regulatory approval and production of the implant, while also gaining marketing rights in the US. Shire retains an option to market and distribute the product outside the US and would be entitled to royalties on US sales and on sales in those markets where Shire does not exercise this option. Further terms of the transaction were not disclosed.
Rolf Stahel, Chief Executive of Shire, said: ?This renegotiated agreement reflects the best future interests of both parties.?
Dr David S Tierney, HydroMed's President and CEO, noted: "The Histrelin implant employs our Company's patented and proprietary Hydron? Implant technology and today's announcement represents a significant milestone, because it enriches our product development program and substantially enhances our longer term growth prospects."
Most read news
Other news from the department research and development
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.